Dry Powder Inhalers Linked to Better COPD Outcomes, Lower Eco Impact

UCLA Health study finds dry powder and soft mist inhalers associated with slightly improved clinical results compared to metered-dose inhalers.

Published on Feb. 24, 2026

Got story updates? Submit your updates here. ›

New research from UCLA Health suggests that certain inhalers used to treat chronic obstructive pulmonary disease (COPD) are not only less harmful to the environment but can also lead to slightly better patient outcomes. The study found that dry powder and soft mist inhalers, which do not use propellants that are potent greenhouse gases, were associated with a lower risk of COPD exacerbations compared to metered-dose inhalers (MDIs) in the same therapeutic class. The dry powder inhaler, umeclidinium-vilanterol, was associated with a 14% lower risk of moderate or severe COPD exacerbations compared to the MDI, glycopyrrolate-formoterol.

Why it matters

Inhalers are essential therapies for COPD and other lung conditions, but many commonly used devices rely on propellants that are potent greenhouse gases. This study highlights an opportunity to reduce healthcare-related emissions while potentially improving patient care by shifting to lower-emission inhaler options.

The details

Researchers analyzed insurance claims data from 2016 to 2025 to compare the clinical outcomes and safety of three common COPD inhalers - the dry powder inhaler umeclidinium-vilanterol, the soft mist inhaler tiotropium-olodaterol, and the metered-dose inhaler glycopyrrolate-formoterol. They found the dry powder inhaler was associated with a 14% lower risk of moderate or severe COPD exacerbations compared to the MDI, while the soft mist inhaler had a 6% lower risk. Safety outcomes were similar across all groups.

  • The data analyzed covered prescriptions from 2016 to 2025.

The players

UCLA Health

A leading academic medical center and health system based in Los Angeles, California.

Dr. William Feldman

A pulmonologist and health services researcher at UCLA Health who was the senior author of the study.

Got photos? Submit your photos here. ›

What they’re saying

“The inhalers we studied are the first line treatment for many patients with COPD, so it's reassuring to see evidence that lower-emission inhalers may also be associated with slightly better clinical outcomes.”

— Dr. William Feldman, Pulmonologist and health services researcher

“This combination makes a strong case for using the dry powder inhaler when possible. Although some patients may require MDIs, dry powder inhalers and soft mist inhalers are a safe and effective option for most patients with COPD.”

— Dr. William Feldman, Pulmonologist and health services researcher

What’s next

The researchers plan to further investigate the potential environmental and clinical benefits of switching COPD patients to lower-emission inhaler options.

The takeaway

This study suggests that transitioning COPD patients from metered-dose inhalers to dry powder or soft mist inhalers could lead to slightly improved clinical outcomes while also reducing the environmental impact of these essential medical devices.